Interaction of 4,4-difluoro-1,3,7,8-tetramethyl-2,6-disulfo-4-bora-3a,4a-diaza-s-indacene sodium salt (BODIPY, BP1) with bovine serum albumin (BSA) and human serum albumin (HSA) was investigated using spectral methods and molecular docking. It was shown that BP1 forms stable supramolecular complexes with BSA and HSA predominantly due to the specific interactions. Supramolecular complex formation was accompanied by strong fluorescence quenching of BP1 as a result of FRET. This effect could be used for the qualitative and quantitative detection of HSA in model physiological fluids. The detection limit of BSA and HSA were 0.26 and 0.05 mg·mL^-1, respectively. The selectivity of BP1 fluorescence response to the co-presence of BSA and HSA in solution was demonstrated. The BP1 fluorescent probe was successfully used for the qualitative and quantitative detection of HSA in human urine samples. The obtained results indicated the capability of using BP1-based fluorescent sensors in clinical medicine for early detection of microalbuminuria and concomitant diseases.

4,4-difluoro-1,3,7,8-tetramethyl-2,6-disulfo-4-bora-3a,4a- diaza - s - indacene钠盐（BODIPY，BP1）与牛血清白蛋白（BSA）的相互作用) 和人血清白蛋白 (HSA) 使用光谱方法和分子对接进行了研究。结果表明，BP1与 BSA 和 HSA 形成稳定的超分子复合物，主要是由于特定的相互作用。由于 FRET，超分子复合物的形成伴随着BP1的强荧光猝灭。这种效应可用于模型生理液中 HSA 的定性和定量检测。BSA和HSA的检出限分别为0.26和0.05 mg·mL ^-1。BP1的选择性证明了对溶液中 BSA 和 HSA 共存的荧光响应。该BP1荧光探针成功用于人尿样品中的定性和定量检测人血清白蛋白。获得的结果表明在临床医学中使用基于BP1的荧光传感器早期检测微量白蛋白尿和伴随疾病的能力。